RedHill Biopharma (RDHL) Total Non-Current Liabilities (2011 - 2025)
RedHill Biopharma (RDHL) reported Total Non-Current Liabilities of $1.9 million for Q4 2025, up 268.99% year-over-year from $503000.0 in Q4 2024, and up 271.2% quarter-over-quarter from $500000.0 in Q2 2025.
RedHill Biopharma (RDHL) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has 15 years of Total Non-Current Liabilities data on file, last reported at $1.9 million in Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $1.9 million, up 268.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 million (up 268.99% YoY), and the FY2025 annual result was $1.9 million, up 268.99% from the prior year.
- Total Non-Current Liabilities climbed to $1.9 million in Q4 2025 per RDHL's latest filing, from $500000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $94.9 million in Q2 2021 and troughed at $500000.0 in Q2 2025.
- A 5-year average of $21.7 million and a median of $2.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities tumbled 89.86% in 2023, then soared 268.99% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $90.8 million in 2021, then plunged by 89.19% to $9.8 million in 2022, then plunged by 89.86% to $995000.0 in 2023, then plunged by 49.45% to $503000.0 in 2024, then soared by 268.99% to $1.9 million in 2025.
- Business Quant data shows RDHL's Total Non-Current Liabilities at $1.9 million in Q4 2025, $500000.0 in Q2 2025, and $503000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | RedHill Biopharma | 142.34 Mn | 142.34 Mn | - | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.86 Mn |
| Jun 30, 2025 | 500,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Jun 30, 2024 | 730,000.00 |
| Dec 31, 2023 | 995,000.00 |
| Jun 30, 2023 | 3.38 Mn |
| Dec 31, 2022 | 9.82 Mn |
| Jun 30, 2022 | 13.49 Mn |
| Dec 31, 2021 | 90.84 Mn |
| Jun 30, 2021 | 94.92 Mn |
| Dec 31, 2020 | 93.14 Mn |
| Jun 30, 2020 | 95.91 Mn |
| Dec 31, 2019 | 3.48 Mn |
| Jun 30, 2019 | 3.74 Mn |
| Dec 31, 2018 | 844,000.00 |
| Dec 31, 2017 | 448,000.00 |
| Dec 31, 2016 | 10.45 Mn |
| Sep 30, 2016 | 7.34 Mn |
| Jun 30, 2016 | 6.22 Mn |
| Mar 31, 2016 | 5.56 Mn |